Browse USP44

Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Peaks in interphase, with relatively low levels maintained throughout mitosis.
Domain PF00443 Ubiquitin carboxyl-terminal hydrolase
PF02148 Zn-finger in ubiquitin-hydrolases and other protein
Function

Deubiquitinase that plays a key regulatory role in the spindle assembly checkpoint or mitotic checkpoint by preventing premature anaphase onset. Acts by specifically mediating deubiquitination of CDC20, a negative regulator of the anaphase promoting complex/cyclosome (APC/C). Deubiquitination of CDC20 leads to stabilize the MAD2L1-CDC20-APC/C ternary complex (also named mitotic checkpoint complex), thereby preventing premature activation of the APC/C. Promotes association of MAD2L1 with CDC20 and reinforces the spindle assembly checkpoint. Acts as a negative regulator of histone H2B (H2BK120ub1) ubiquitination.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000075 cell cycle checkpoint
GO:0000819 sister chromatid segregation
GO:0007059 chromosome segregation
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007091 metaphase/anaphase transition of mitotic cell cycle
GO:0007093 mitotic cell cycle checkpoint
GO:0007094 mitotic spindle assembly checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0010498 proteasomal protein catabolic process
GO:0010639 negative regulation of organelle organization
GO:0010948 negative regulation of cell cycle process
GO:0010965 regulation of mitotic sister chromatid separation
GO:0016579 protein deubiquitination
GO:0030071 regulation of mitotic metaphase/anaphase transition
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031577 spindle checkpoint
GO:0033044 regulation of chromosome organization
GO:0033045 regulation of sister chromatid segregation
GO:0033046 negative regulation of sister chromatid segregation
GO:0033047 regulation of mitotic sister chromatid segregation
GO:0033048 negative regulation of mitotic sister chromatid segregation
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044784 metaphase/anaphase transition of cell cycle
GO:0045786 negative regulation of cell cycle
GO:0045839 negative regulation of mitotic nuclear division
GO:0045841 negative regulation of mitotic metaphase/anaphase transition
GO:0045930 negative regulation of mitotic cell cycle
GO:0051304 chromosome separation
GO:0051306 mitotic sister chromatid separation
GO:0051348 negative regulation of transferase activity
GO:0051438 regulation of ubiquitin-protein transferase activity
GO:0051444 negative regulation of ubiquitin-protein transferase activity
GO:0051783 regulation of nuclear division
GO:0051784 negative regulation of nuclear division
GO:0051983 regulation of chromosome segregation
GO:0051985 negative regulation of chromosome segregation
GO:0070646 protein modification by small protein removal
GO:0071173 spindle assembly checkpoint
GO:0071174 mitotic spindle checkpoint
GO:0090231 regulation of spindle checkpoint
GO:0090266 regulation of mitotic cell cycle spindle assembly checkpoint
GO:0098813 nuclear chromosome segregation
GO:1901976 regulation of cell cycle checkpoint
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902099 regulation of metaphase/anaphase transition of cell cycle
GO:1902100 negative regulation of metaphase/anaphase transition of cell cycle
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903504 regulation of mitotic spindle checkpoint
GO:1904666 regulation of ubiquitin protein ligase activity
GO:1904667 negative regulation of ubiquitin protein ligase activity
GO:2000816 negative regulation of mitotic sister chromatid separation
GO:2001251 negative regulation of chromosome organization
Molecular Function GO:0004843 thiol-dependent ubiquitin-specific protease activity
GO:0008234 cysteine-type peptidase activity
GO:0019783 ubiquitin-like protein-specific protease activity
GO:0036459 thiol-dependent ubiquitinyl hydrolase activity
GO:0101005 ubiquitinyl hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between USP44 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of USP44 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of USP44 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.3380.043
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3950.254
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2640.4
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0420.944
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7410.411
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5340.623
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1850.671
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.420.516
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2340.374
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of USP44 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of USP44. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of USP44. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by USP44.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of USP44. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of USP44 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between USP44 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUSP44
Nameubiquitin specific peptidase 44
Aliases FLJ14528; ubiquitin specific protease 44; deubiquitinating enzyme 44; ubiquitin thioesterase 44; ubiquitin t ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting USP44 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.